Mirador Therapeutics
Vika Brough currently serves as the Chief Financial Officer at Mirador Therapeutics. Prior to this, Vika held the position of Senior Vice President of Finance at Prometheus Biosciences, Inc. Also, Vika has experience as the Vice President of Finance/Controller at Human Longevity, Inc. Vika's earlier career includes serving as an Audit Senior Manager at EY. Vika holds a Bachelor of Business Administration (B.B.A.) in Accounting from San Diego State University. Additionally, Vika is a member of the Board of Advisors at Life Science Cares San Diego.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.